SCHEMBL21248065

SCHEMBL21248065

C[C]1C=Cc2ccc3ccccc3c21

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES1 P23141 2/20 0.56
CYP2A6 P11509 4/20 0.44
TSHR P16473 4/20 0.44
ALDH1A1 P00352 4/20 0.44
HSD17B10 Q99714 4/20 0.44
TDP1 Q9NUW8 1/20 0.44
MAPT P10636 1/20 0.44
CYP1A2 P05177 2/20 0.43
HPRT1 P00492 1/20 0.41
HIF1A Q16665 2/20 0.39
HPGD P15428 2/20 0.39
CYP3A4 P08684 1/20 0.39
MAPK1 P28482 1/20 0.39
CASP1 P29466 1/20 0.39
RAB9A P51151 1/20 0.39
CASP7 P55210 1/20 0.39
ATM Q13315 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
WDR5 P61964 1/20 0.38
CYP1B1 Q16678 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1055359 0.75 CES1 (0.56) CES1CYP2A6TSHRALDH1A1HSD17B10
SCHEMBL5716919 0.75 CES1 (0.79) CES1CYP2A6TSHRALDH1A1HSD17B10
SCHEMBL22982205 0.75 CES1 (0.51) CES1CYP2A6TSHRALDH1A1HSD17B10
SCHEMBL22982325 0.75 CES1 (0.51) CES1CYP2A6TSHRALDH1A1HSD17B10
SCHEMBL380656 0.72 CES1 (1.00) CES1CYP2A6TSHRALDH1A1HSD17B10
SCHEMBL22983050 0.72 CES1 (0.49) CES1CYP2A6TSHRALDH1A1HSD17B10
SCHEMBL22982204 0.72 CES1 (0.49) CES1CYP2A6TSHRALDH1A1HSD17B10
SCHEMBL22982056 0.71 CES1 (0.47) CES1CYP2A6TSHRALDH1A1HSD17B10
SCHEMBL816043 0.70 ALDH1A1 (0.55) CES1CYP2A6TSHRALDH1A1HSD17B10
SCHEMBL2951616 0.70 TSHR (0.65) CYP2A6TSHRALDH1A1HSD17B10TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11661465-B2 Dimer selective metallocene catalysts, non-aromatic hydrocarbon soluble activators, and processes to produce poly alpha-olefin oligmers therewith EXXONMOBIL CHEMICAL PATENTS INC. (US) 2023-05-30 US disclosed
EP-4010385-A1 PROCESS TO PRODUCE LOW VISCOSITY POLYALPHAOLEFINS USING NON-AROMATIC-HYDROCARBON SOLUBLE ACTIVATORS ExxonMobil Chemical Patents Inc. (US) 2022-06-15 EP disclosed
WO-2021086926-A1 DIMER SELECTIVE METALLOCENE CATALYSTS, NON-AROMATIC HYDROCARBON SOLUBLE ACTIVATORS, AND PROCESSES TO PRODUCE POLY ALPHA-OLEFIN OLIGMERS THEREWITH EXXONMOBIL CHEMICAL PATENTS INC. (US) 2021-05-06 WO disclosed
US-20210122859-A1 Dimer Selective Metallocene Catalysts, Non-Aromatic Hydrocarbon Soluble Activators, And Processes To Produce Poly Alpha-Olefin Oligmers Therewith EXXONMOBIL CHEMICAL PATENTS INC (US) 2021-04-29 US disclosed
WO-2021030045-A1 PROCESS TO PRODUCE LOW VISCOSITY POLYALPHAOLEFINS USING NON-AROMATIC-HYDROCARBON SOLUBLE ACTIVATORS EXXONMOBIL CHEMICAL PATENTS INC. (US) 2021-02-18 WO disclosed
EP-3752540-A1 CATALYST SYSTEMS AND PROCESSES FOR POLY ALPHA-OLEFIN HAVING HIGH VINYLIDENE CONTENT ExxonMobil Chemical Patents Inc. (US) 2020-12-23 EP disclosed
WO-2019157169-A1 CATALYST SYSTEMS AND PROCESSES FOR POLY ALPHA-OLEFIN HAVING HIGH VINYLIDENE CONTENT EXXONMOBIL CHEMICAL PATENTS INC. (US) 2019-08-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11661465-B2 Dimer selective metallocene catalysts, non-aromatic hydrocarbon soluble activators, and processes to produce poly alpha-olefin oligmers therewith NONO, TPR, ZNF787 CES1 4771/4885CYP2A6 1407/4885TSHR 1988/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.